Viva Biotech Holdings (HKG:1873)
Hong Kong · Delayed Price · Currency is HKD 1.300
+0.040 (3.17%)
Jul 31, 2026, 4:08 PM HKT
Viva Biotech Holdings Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,729 | 1,729 | 1,987 | 2,156 | 2,380 | 2,104 |
Revenue Growth | -5.84% | -12.95% | -7.84% | -9.41% | 13.10% | 201.89% |
Gross Profit Gross Profit Growth | 655.56 | 655.56 | 687.4 | 738.43 | 815.68 | 650.98 |
Operating Income Operating Income Growth | 193.25 | 193.25 | 229.67 | 192.68 | 265.98 | 236.9 |
Net Income Net Income Growth | 219.76 | 219.76 | 167.29 | -116.11 | -528.48 | 287.55 |
Earnings Per Share EPS Growth | 0.09 | 0.09 | 0.06 | -0.14 | -0.28 | 0.08 |
EPS Growth | 44.22% | 50.00% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Contract Development Manufacture Organisation (CDMO) and Commercialisation Services Contract Development Manufacture Organisation (CDMO) and Commercialisation Services Growth | 894.11 | 894.11 | 1,179 | 1,315 | 1,485 | 1,364 |
Drug Discovery Services Drug Discovery Services Growth | 854.72 | 854.72 | 821.31 | 866.76 | 895.06 | 740.47 |
Elimination Elimination Growth | -28.69 | -28.69 | -32.09 | -56.54 | - | - |
Viva Bioinnovator Viva Bioinnovator Growth | 9.31 | 9.31 | 18.09 | 30.61 | - | - |
Total Total Growth | 1,729 | 1,729 | 1,987 | 2,156 | 2,380 | 2,104 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,089 | 1,089 | 941.71 | 1,036 | 678.57 | 800.95 |
Total Debt Total Debt Growth | 1,331 | 1,331 | 1,284 | 1,903 | 2,823 | 2,655 |
Net Cash (Debt) Net Cash Growth | -241.82 | -241.82 | -342.34 | -866.9 | -2,144 | -1,854 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.10 | -0.10 | -0.12 | -0.43 | -1.12 | -0.94 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 232.23 | 232.23 | 373.99 | 383.41 | 386.05 | 77.83 |
Capital Expenditures CapEx Growth | -121.16 | -121.16 | -190.67 | -187.68 | -249.33 | -565.18 |
Free Cash Flow Free Cash Flow Growth | 111.07 | 111.07 | 183.32 | 195.73 | 136.72 | -487.35 |
Free Cash Flow Growth | -48.18% | -39.41% | -6.34% | 43.16% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 37.91% | 37.91% | 34.60% | 34.26% | 34.28% | 30.94% |
Operating Margin | 11.17% | 11.17% | 11.56% | 8.94% | 11.18% | 11.26% |
Pretax Margin | 18.39% | 18.39% | 14.88% | -2.60% | -19.30% | 16.53% |
Profit Margin | 12.71% | 12.71% | 8.42% | -5.39% | -22.21% | 13.67% |
FCF Margin | 6.42% | 6.42% | 9.23% | 9.08% | 5.75% | -23.16% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.98 | 15.53 | 10.21 | - | - | 25.63 |
Forward PE | 6.76 | 5.15 | 5.15 | 5.15 | 5.17 | 10.88 |
P/FCF Ratio | 21.82 | 30.73 | 9.32 | 10.43 | 21.69 | - |
PS Ratio | 1.40 | 1.97 | 0.86 | 0.95 | 1.25 | 3.50 |